Tags: Intellectual Property
IP license agreements: common pitfalls and key issues
Learn how to identify and address key issues in licensing agreements to avoid legal headaches!
Trademark protection in Web 3.0: Lessons from the Hermès vs. MetaBirkins case
On 8 February 2023, a New York jury delivered its long-awaited verdict in a case brought by the French luxury brand Hermès, against the artist Mason Rothschild.
When are IP holders liable for enforcing a later invalidated IP right?
At this IP Update, our IP specialists, Christophe Ronse and Kirian Claeyé, will discuss under what circumstances IP holders may be held liable for enforcing a later invalidated IP right.
WEBINAR VIDEO | What do the CJEU’s decisions on parallel trade of medicines mean for your company?
At this additional Christmas edition, the IP specialists in our Life Sciences team discuss the CJEU’s latest decisions on the parallel trade of medicines, and what these decisions mean in practice for your company. On 17 November 2022, the CJEU delivered essentially two decisions on the parallel trade of medicines. The first concerned the rebranding […]
What do the CJEU’s decisions on parallel trade of medicines mean for your company?
At this additional Christmas edition, the IP specialists in our Life Sciences team will discuss the CJEU’s latest decisions on the parallel trade of medicines, and what these decisions mean in practice for your company.
Are parallel importers necessarily allowed to rebox medicines in case of visible traces from ATDs? The CJEU says NO
Pharmaceutical companies are obliged to affix an anti-tampering device (‘ATD’) on prescription-only medicines to enable verification of whether a medicine’s packaging has been tampered with. Parallel importers argue that this results in an overarching objective necessity to ‘rebox’ such medicines.
Can parallel importers (re)brand generic medicines? The CJEU limits the ‘room for manoeuvre’
If a branded medicine and its generic version are put on the EEA market by economically-linked undertakings, is a parallel importer then allowed to rebrand and repackage the imported generic version as the branded reference medicine? After the Brussels Court of Appeal had referred questions on this issue for a preliminary ruling two years ago, the CJEU has now clarified the limits.
Copyright fit for the internet age? Belgium implements the DSM directive (Part 3: New rules governing copyright contracts)
On 1 August 2022, the Belgian law transposing the Directive on Copyright in the Digital Single Market (“DSM directive”) (EU Directive 2019/790) was published in the Belgian State Gazette (NL / FR). The new law enters into effect immediately (with the exception of a few provisions).
Copyright fit for the internet age? Belgium implements the DSM directive (Part 2: New neighbouring right for press publishers & four new mandatory exceptions to copyright)
On 1 August 2022, the Belgian law transposing the Directive on Copyright in the Digital Single Market (“DSM directive”) (EU Directive 2019/790) was published in the Belgian State Gazette (NL / FR). The new law enters into effect immediately (with the exception of a few provisions).
Copyright fit for the internet age? Belgium implements the DSM directive (Part 1: Background & article 17 DSM directive)
On 1 August 2022, the Belgian law transposing the Directive on Copyright in the Digital Single Market (“DSM directive”) (EU Directive 2019/790) was published in the Belgian State Gazette. The new law enters into effect immediately (with the exception of a few provisions).
WEBINAR VIDEO | IP UPDATE #4: TRADE SECRETS – BE AWARE AND BE PAREPARED
What is a trade secret? How does a trade secret differ from an intellectual property right and why choose one over the other? What measures should a company implement to best protect its trade secrets? What measures are available in the event of a breach and how can you ensure that the secret is not […]